Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Non-Opioid Pain Patch Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The non-opioid pain patch market has seen consistent growth in its size over recent years. It is projected to expand from $3.63 billion in 2025 to $3.79 billion in 2026, indicating a compound annual growth rate (CAGR) of 4.6%. This market’s historical growth can be attributed to concerns about opioid dependency, an increasing occurrence of musculoskeletal disorders, an expanding aging population, the development of retail pharmacy networks, and physicians’ inclination towards localized pain treatment.
The non-opioid pain patch market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $4.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.5%. This forecasted growth is driven by several factors, including the increasing occurrence of chronic pain, enhanced regulatory backing for non-opioid treatments, breakthroughs in transdermal drug delivery systems, rising patient understanding of non-addictive options, and the broadening of applications to include neuropathic pain. Key developments expected during this period involve a growing inclination towards non-addictive pain relief, increased use of topical and localized treatments, the proliferation of both over-the-counter and prescription hybrid patches, a greater need for chronic pain management solutions, and innovations in patch adherence and drug release duration.
Get A Free Sample Report With In-Depth Market Insights:
Non-Opioid Pain Patch Market Growth Backed By Core Demand Fundamentals
The increasing occurrence of chronic pain is projected to drive the expansion of the non-opioid pain patch market in the future. Chronic pain is defined as intense discomfort persisting over a prolonged duration or associated with an existing medical ailment. These patches, free from opioids, are utilized for alleviating mild to moderate discomfort, addressing conditions such as headaches, muscle pain, arthritis, backaches, and various other forms of pain. A concrete example from November 2024 highlights this trend: the Centers for Disease Control and Prevention, a national public health agency based in the US, reported that approximately 24.3% of adults had chronic pain in 2023. Of these, 8.5%, which is about one-third, experienced high-impact chronic pain, with a greater incidence observed in women compared to men. Consequently, the increasing prevalence of chronic pain is actively stimulating the non-opioid pain patch market.
Non-Opioid Pain Patch Market Segment Trends And Revenue Contributors
The non-opioid pain patch market covered in this report is segmented –
1) By Patch: Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, Other Patches
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
3) By Indication: Musculoskeletal Pain, Neuropathic Pain
Subsegments:
1) By Lidocaine Patches: 5% Lidocaine Patch, Other Concentrations
2) By Diclofenac Patches: 1.3% Diclofenac Patch, Other Concentrations
3) By Capsaicin Patches: 8% Capsaicin Patch, Other Concentrations
4) By Ketoprofen Patches: 5% Ketoprofen Patch, Other Concentrations
5) By Other Patches: Combination Patches, Herbal Extract Patches, Other Non-Opioid Patches
Non-Opioid Pain Patch Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the non-opioid pain patch market are actively engaged in developing innovative products, including medicines based on genetically validated targets. This approach entails creating drugs that specifically address biological pathways directly linked to a disease, supported by strong genetic evidence, which enhances treatment effectiveness and reduces the likelihood of side effects. As an illustration, in February 2024, Latigo Biotherapeutics Inc., a US-based biotechnology company, launched LTG-001. This substance acts as a selective inhibitor of the Nav1.8 sodium channel, primarily found in peripheral nerve cells. By targeting this specific channel, LTG-001 aims to block pain signals where they originate, potentially offering effective pain relief without impacting the central nervous system. The outcomes of its Phase 1 clinical trial demonstrated that LTG-001 achieved a Tmax (time to maximum concentration) of roughly 1.5 hours, indicating a rapid commencement of pain relief. This feature holds significant importance for managing both acute and chronic pain. Additionally, LTG-001 is formulated for oral administration, providing patients with a convenient option compared to injectable or topical therapies, thereby enhancing patient compliance and ease of use.
Non-Opioid Pain Patch Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the non-opioid pain patch market are Hisamitsu Pharmaceutical Co. Inc., Teikoku Pharma USA Inc., Noven Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., Grünenthal GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Iroko Pharmaceuticals LLC, Scilex Pharmaceuticals Inc., Zosano Pharma Corporation, Adynxx Inc., BioElectronics Corporation, NeuroMetrix Inc., Virpax Pharmaceuticals Inc., Novartis AG, DURECT Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc.
View The Full Non-Opioid Pain Patch Market Report:
Non-Opioid Pain Patch Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the non-opioid pain patch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in the non-opioid pain patch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model